RxDoctor Payments Data

Sami Nazzal, MD

Interventional Cardiology · San Bernardino, CANPI 1053385575

Payments from drug & device makers

$12,322in general payments, 2019–2025

Across 224 payments — averaging $55.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$7K
  • Bayer$2K
  • Novartis$513
  • Merck$408
  • AstraZeneca$364
  • Abbott$230
  • plus $2K from 30 others

What the payments were for

  • Speaking & faculty fees$7,37060%
  • Travel & lodging$6685%
  • Food & beverage$4,18834%
  • Education$961%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,322 in reported general payments places this provider in the 50th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$179,589
Medicare patients
1,152
Services billed
2,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban173$196,182
EntrestoSacubitril/Valsartan128$173,495
XareltoRivaroxaban105$126,975
BrilintaTicagrelor149$110,404
AdempasRiociguat11$103,233
JardianceEmpagliflozin65$69,262
FarxigaDapagliflozin Propanediol18$22,465
Metoprolol Succinate539$7,207
DexilantDexlansoprazole14$3,818
Rosuvastatin Calcium150$3,249
Atorvastatin Calcium277$3,193
Losartan Potassium194$2,651
Amlodipine Besylate328$2,448
Ranolazine ErRanolazine24$2,300
Carvedilol216$2,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$116$196,182173 claims
NovartisEntresto$513$173,495128 claims
AstraZenecaBrilinta, Farxiga$364$132,869167 claims
Johnson & JohnsonXarelto$6,649$126,975105 claims
BayerAdempas$1,824$103,23311 claims
Boehringer IngelheimJardiance$171$69,26265 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in San Bernardino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →